Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Daban A, Gonnin C, Phan L, Saldmann A, Granier C, Lillo-Lelouet A, Le Beller C, Pouchot J, Weiss L, Tartour E, Fabre E, Medioni J, Oudard S, Vano YA, Dragon-Durey MA, Simonaggio A.
Daban A, et al.
Oncoimmunology. 2023 May 11;12(1):2204754. doi: 10.1080/2162402X.2023.2204754. eCollection 2023.
Oncoimmunology. 2023.
PMID: 37187974
Free PMC article.